On December 13|Clover Bio-B (02197.HK) announced that in the phase I human clinical trial evaluating the company's respiratory syncytial virus (“RSV”) PreF - trimeric subunit vaccine candidate (SCB-1019), the first batch of subjects had completed enrollment. The vaccine candidate was developed based on the company's unique and innovative protein trimerization (Trimer-Tag) vaccine technology platform.
According to the disclosure, SCB-1019 is a bivalent recombinant protein RSV candidate vaccine containing two F antigens (A and B subtype RSVF proteins) with stable pre-fusion conformations, a proven Trimer-tag vaccine technology platform, and a highly stable preF mutation that has applied for a patent. The phase I clinical trial initiated in Australia is a randomized, placebo-controlled study to evaluate the safety, reactogenicity, and immunogenicity of SCB-1019 in different dosage forms and dosage levels among young adults and older adults. Safety and immunogenicity results are expected to be published in the second half of 2024.